This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, L. Articles by Tannock, I. F Search for Related Content PubMed PubMed Citation Articles by Wu, L. Articles by Tannock, I. F

Repopulation in Murine Breast Tumors during and after Sequential Treatments with Cyclophosphamide and 5-Fluorouracil¹

Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, M5G 2M9 Canada

The rate of repopulation of surviving cells increases during fractionated radiotherapy and limits the ability to control tumors. Repopulation is likely to be more important during the longer intervals between courses of chemotherapy and is a potential cause of clinical resistance to chemotherapy. To evaluate the rate of repopulation of surviving cells in MXT and EMT-6 mouse breast tumors between successive cycles of chemotherapy, tumor-bearing mice were treated with up to three weekly cycles of cyclophosphamide or 5-fluorouracil (5FU). Animals were killed at different intervals during and after chemotherapy, and uptake of 5'bromodeoxyuridine and immunohistochemical staining were selected to study repopulation. When tumors regrew after a single treatment, the proliferative rate of tumor cells returned to control values. During successive courses of chemotherapy, the proliferative rate of surviving cells increased in both tumors, e.g., in 5FU-treated MXT tumors, the percentages of 5'bromodeoxyuridine-labeled proliferating cells at 7 days after the first, second, and third treatment were 25 ± 12%, 29 ± 9%, and 27 ± 11%; it was 32 ± 6% at 14 days after the third treatment. The corresponding value in control tumors was 19 ± 2% (P < 0.05 for each comparison). Accelerating repopulation after sequential treatments with cyclophosphamide or 5FU can lead to effective drug resistance in the absence of changes in the sensitivity of constituent cells.

This article has been cited by other articles:

				A. S. Fung, L. Wu, and I. F. Tannock Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts Clin. Cancer Res., September 1, 2009; 15(17): 5389 - 5395. [Abstract] [Full Text] [PDF]

				A. L. Kesner, W.-A. Hsueh, N. L. Htet, B. S. Pio, J. Czernin, M. D. Pegram, M. E. Phelps, and D. H.S. Silverman Biodistribution and Predictive Value of 18F-Fluorocyclophosphamide in Mice Bearing Human Breast Cancer Xenografts J. Nucl. Med., December 1, 2007; 48(12): 2021 - 2027. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann. Onc., April 1, 2006; 17(4): 543 - 552. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, S. M. Bentzen, A. Minken, R. Wanders, L. Lutgens, M. Hochstenbag, L. Boersma, B. Wouters, G. Lammering, et al. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1057 - 1063. [Abstract] [Full Text] [PDF]

				L. Wu and I. F. Tannock Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy Clin. Cancer Res., November 15, 2005; 11(22): 8195 - 8200. [Abstract] [Full Text] [PDF]

				Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C. R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R. S. Kerbel Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy Cancer Res., August 15, 2005; 65(16): 7045 - 7051. [Abstract] [Full Text] [PDF]

				P. Wong, C. Lee, and I. F. Tannock Reduction of Intracellular pH as a Strategy to Enhance the pH-Dependent Cytotoxic Effects of Melphalan for Human Breast Cancer Cells Clin. Cancer Res., May 1, 2005; 11(9): 3553 - 3557. [Abstract] [Full Text] [PDF]

				L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]

				I. F. Tannock Limited Drug Access and Repopulation of Surviving Tumor Cells between Courses of Chemotherapy: Important and Neglected Causes of Clinical Drug Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 103 - 107. [Full Text] [PDF]

				W. Licun and I. F. Tannock Selective Estrogen Receptor Modulators as Inhibitors of Repopulation of Human Breast Cancer Cell Lines after Chemotherapy Clin. Cancer Res., October 1, 2003; 9(12): 4614 - 4618. [Abstract] [Full Text] [PDF]